TABLE 4.
Primary and Secondary Outcomes According to Erythema, Induration, Fever, Type of Procedure, Location of Infection, Gender, and Age
| Primary Outcome: Improved at 48–72 h (n = 194), % (n/N)a | P | Secondary Outcome: Resolved at 7 d (n = 191), % (n/N)a | P | |
|---|---|---|---|---|
| Erythema | .27 | .27 | ||
| <5 cm | 96% (134/139) | 96% (132/137) | ||
| >5 cm | 93% (51/55) | 93% (50/54) | ||
| Induration | .71 | .58 | ||
| <5 cm | 95% (156/164) | 96% (154/161) | ||
| >5 cm | 97% (29/30) | 93% (28/30) | ||
| Fever present | .03b | .03b | ||
| Yes | 89% (42/47) | 89% (42/47) | ||
| No | 97% (143/147) | 97% (140/144) | ||
| Procedure | .43 | 1.00 | ||
| ID | 94% (117/125) | 95% (117/123) | ||
| EP, no ID | 98% (63/64) | 95% (60/63) | ||
| None | 100% (5/5) | 100% (5/5) | ||
| Location of infection | .09 | .31 | ||
| Above waist | 99% (78/79) | 97% (77/79) | ||
| Below waist | 93% (107/115) | 94% (105/112) | ||
| Gender | 1.00 | 1.00 | ||
| Male | 96% (79/83) | 95% (77/81) | ||
| Female | 95% (106/111) | 95% (105/110) | ||
| Age | .004b | .17 | ||
| 6–12 mo | 76% (13/17) | 88% (14/16) | ||
| >1 year | 97% (172/177) | 96% (168/175) |
EP, expressed pus.
a
The total N for both the primary and secondary outcome variable is <200 owing to subjects lost to follow-up.
b
Statistically significant.